期刊
BRITISH JOURNAL OF PSYCHIATRY
卷 210, 期 2, 页码 119-124出版社
CAMBRIDGE UNIV PRESS
DOI: 10.1192/bjp.bp.116.188078
关键词
-
类别
资金
- National Institute of Mental Health (NIMH) [R01 MH070884, U01-MH60220]
- John D. and Catherine T. MacArthur Foundation
- Pfizer Foundation
- US Public Health Service [R13-MH066849, R01-MH069864, R01 DA016558]
- Fogarty International Center [FIRCA R03-TW006481]
- Pan American Health Organization
- Eli Lilly and Company
- Ortho-McNeil Pharmaceutical
- GlaxoSmithKline
- Sanofi Aventis
- Bristol-Myers Squibb
- Argentinian Ministry of Health (Ministerio de Salud de la Nacion)
- National Center for Public Health Protection
- Ministry of Health
- Ministry of Social Protection
- Center for Excellence on Research in Mental Health (CES University)
- Secretary of Health of Medellin
- European Commission [QLGS-1999-01042, SANCO 2004123, EAHC 20081308]
- European Commission (Piedmont Region (Italy))
- Fondo de Investigacion Sanitaria
- Instituto de Salud Carlos III, Spain [FIS 00/0028]
- Ministerio de Ciencia y Tecnologia, Spain [SAF 2000-158-CE]
- Departament de Salut
- Generalitat de Catalunya, Spain
- Institute de Salud Carlos III [CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP]
- European Funds through United Nations Development Group Iraq Trust Fund (UNDG ITF)
- Israel National Institute for Health Policy and Health Services Research
- National Insurance Institute of Israel
- Grant for Research on Psychiatric and Neurological Diseases and Mental Health from the Japan Ministry of Health, Labour and Welfare [H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013]
- Lebanese Ministry of Public Health
- WHO (Lebanon)
- National Institute of Health/Fogarty International Center [R03 TW006481-01]
- Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences
- AstraZeneca
- Eli Lilly
- Hikma Pharmaceuticals
- Janssen Cilag
- Lundbeck
- Novartis
- Servier
- National Institute of Psychiatry Ramon de la Fuente [INPRFMDIES 4280]
- National Council on Science and Technology [CONACyT-G30544-H]
- Regional Health Authorities of Murcia (Servicio Murciano de Salud and Consejeria de Sanidad y Politica Social)
- Fundacion pars la Formacion e Investigacion Sanitarias (FFIS) of Murcia
- WHO (Geneva)
- WHO (Nigeria)
- Federal Ministry of Health, Abuja, Nigeria
- National Institute of Health of the Ministry of Health of Peru
- Champalimaud Foundation
- Gulbenkian Foundation
- Foundation for Science and Technology (FCT)
- Ministry of Public Health
- State of Sao Paulo Research Foundation (FAPESP) Thematic Project Grant The Brazilian National Council for Scientific and Technological Development [03/00204-3, 307623/2013-0]
- Robert Wood Johnson Foundation (RWJF) [044708]
- John W Alden Trust
- National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South London at King's College London Foundation Trust
- European Union Seventh Framework Programme Emerald project
- UK aid from the UK Government
- Department of Health via the National Institute for Health Research (NIHR) Biomedical Research Centre
- Dementia Unit
- National Institute for Health Research [NF-SI-0611-10053] Funding Source: researchfish
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [03/00204-3] Funding Source: FAPESP
Background Major depressive disorder (MDD) is a leading cause of disability worldwide. Aims To examine the: (a) 12-month prevalence of DSM-IV MDD; (b) proportion aware that they have a problem needing treatment and who want care; (c) proportion of the latter receiving treatment; and (d) proportion of such treatment meeting minimal standards. Method Representative community household surveys from 21 countries as part of the World Health Organization World Mental Health Surveys. Results Of 51 547 respondents, 4.6% met 12-month criteria for DSM-IV MDD and of these 56.7% reported needing treatment. Among those who recognised their need for treatment, most (71.1%) made at least one visit to a service provider. Among those who received treatment, only 41.0% received treatment that met minimal standards. This resulted in only 16.5% of all individuals with 12-month MDD receiving minimally adequate treatment. Conclusions Only a minority of participants with MDD received minimally adequate treatment: 1 in 5 people in high-income and 1 in 27 in low-/lower-middle-income countries. Scaling up care for MDD requires fundamental transformations in community education and outreach, supply of treatment and quality of services.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据